Early Albumin Infusion Is Associated With Greater Survival to Discharge Among Patients With Sepsis/Septic Shock Who Develop Severe Acute Kidney Injury Among Patients With Sepsis/Septic Shock Who Develop Severe Acute Kidney Injury.

• Type of Material: Article
• Authors: Karthik Raghunathan, Duke University; Jordan A. Kempker, Emory University; E. Anne Davis, Grifols Shared Services North America; Navreet S. Sindhwani, Grifols Shared Services North America; Santosh Telang, Boston Strategic Partners, Inc.; Kunal Lodaya, Boston Strategic Partners, Inc.; Gregory Martin, Emory University
• Language: English
• Date: 2022-12
• Publisher: Wolters Kluwer Health, Inc.
• Publication Version: Final Published Version
• Copyright Statement: © 2022 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1097/CCE.0000000000000793
• Title of Journal or Parent Work: Crit Care Explor
• Volume: 4
• Issue: 12
• Start Page: e0793
• End Page: e0793
• Grant/Funding Information: Supported, in part, by Grifols Shared Services North America.
• Keywords: length of stay; sepsis; human serum albumin; acute kidney injury; septic shock
• Research Categories: Health Sciences, Health Care Management; Health Sciences, Medicine and Surgery

Abstract

UNLABELLED: Adults hospitalized with sepsis/septic shock commonly develop acute kidney injury (AKI) which imposes a significant burden on the healthcare system. The administration of early human albumin in this patient population may yield more efficient healthcare resource utilization. OBJECTIVES: To examine the association between early use of albumin and time to discharge in adults who develop severe AKI while hospitalized with sepsis/septic shock. DESIGN: Retrospective cohort study using de-identified electronic health records from a national database (Cerner Health Facts; Cerner Corp., Kansas City, MO). SETTING AND PARTICIPANTS: Patients (n = 2,829) hospitalized between January 2013 and April 2018 with a diagnosis of sepsis/septic shock (identified using International Classification of Diseases, 9th Revision and 10th Revision codes) who developed severe AKI (stage 3 according to Kidney Disease Improving Global Outcomes criteria) during hospitalization (n = 2,845 unique encounters). MAIN OUTCOMES AND MEASURES: Patients were grouped according to timing of albumin exposure: within less than or equal to 24 hours of admission ("early albumin") or unexposed/exposed late ("nonearly albumin"). A cause-specific hazard model, censoring for death/discharge to hospice, was used to examine the association between "early albumin" and the rate of hospital discharge with clinical stability. RESULTS: Albumin was administered early in 8.6% of cases. Cases with early albumin administration had a median time to discharge of 13.2 days compared with 17.0 in the nonearly group (Log-rank p < 0.0001). An adjusted analysis showed that the rate of hospital discharge with clinical stability increased by 83% in the early albumin group compared with the nonearly group (hazard ratio, 1.832; 95% CI, 1.564-2.146; p < 0.001 nonearly group. CONCLUSIONS AND RELEVANCE: The use of albumin within 24 hours of hospital admission was associated with a shorter time to discharge and a higher rate of discharge with clinical stability, suggesting an improvement in healthcare resource utilization among patients with sepsis/septic shock who developed stage 3 AKI during hospitalization.